French Sanofi's Developed COVID-19 Vaccine Begins Phase 3 Clinical Trial

Sanofi, France
Photo by AP Yonhap News

[Asia Economy Reporter Chunhee Lee] The COVID-19 vaccine jointly developed by France's Sanofi and the United Kingdom's GlaxoSmithKline (GSK) is entering Phase 3 clinical trials.

Sanofi and GSK announced on the 27th (local time) that they will begin Phase 3 clinical trials involving 35,000 adults aged 18 and over across the United States, Asia, Africa, and Latin America.

Sanofi and GSK will verify whether the vaccine candidate is effective against the COVID-19 virus first identified in China, and will also evaluate its efficacy against the South African variant. Additionally, clinical trials will be conducted to confirm whether their vaccine is effective as a booster shot for individuals who have already received vaccines from other companies.

On the 17th, Sanofi and GSK announced that the Phase 2 clinical trial results showed the vaccine candidate elicited a strong immune response across all adult age groups. If positive results continue through Phase 3, the vaccine is expected to be released by the end of this year.

Sanofi and GSK have been attempting vaccine development since the early stages of the COVID-19 pandemic, but the vaccine candidate released last year did not provide sufficient immunity in those aged 50 and above.

This content was produced with the assistance of AI translation services.